Incyte Corporation (NASDAQ: INCY) is falling apart in the market today after announcing that a Phase 3 clinical trial, in collaboration with Merck & Co., Inc. (NYSE: MRK) has ended with less-than-positive data. Of course, this struck fear in the minds of investors, sending the stock tumbling down. Today, we’ll talk about: The clinical results; what we’re … Read more
Eli Lilly and Co (NYSE: LLY) is having an relatively strong start to the trading session this morning after announcing plans to resubmit a New Drug Application with the United States Food and Drug Administration. Of course, this led to excitement among investors who sent the stock toward the top. As is normally the case, … Read more
Incyte Corporation (NASDAQ: INCY) is having an incredibly rough day in the market this morning, and for good reason. A treatment that was expected to be approved by the FDA was rejected, causing investor fears and leading to declines in the stock and prompting our partners at Trade Ideas to alert us to the movement. … Read more
Agenus Inc (NASDAQ: AGEN) | Incyte Corporation (NASDAQ: INCY) Agenus is having an incredibly strong day in the market today. When the trading session started for the day, the stock was already trading well into the green. From there, the stock dipped a bit before a strong continuation of gains was seen in the chart. … Read more
BioCryst Pharmaceuticals (NASDAQ: BCRX) On February 8, 2016 shares of BioCryst Pharmaceuticals fell by more than 71% after the company had announced that it had failed a phase 2 trial. The phase 2 trial known as the OPuS-2 trial recruited a total of 108 patients with Hereditary Angiodema — HAE. HAE is a rare genetic … Read more